Development of palladium-based multivalent lectin-directed artificial metalloenzymes

Area of Science:

• Biochemistry
• Materials Science
• Oncology

Background:

• Artificial metalloenzymes (ArMs) offer potential for targeted cancer prodrug activation.
• Developing ArMs with specific cancer-targeting capabilities is crucial for effective localized therapy.

Purpose of the Study:

• To engineer a multivalent lectin-directed artificial metalloenzyme for cancer therapy.
• To evaluate the biological activity of a novel ArM-prodrug system against hypersialylated breast cancer cells.

Main Methods:

• Construction of a palladium-embedded HaloTag-PduU-ACG lectin fusion protein (HtPA-Pd) as the ArM.
• Combination of the HtPA-Pd ArM with a proc-masked doxorubicin prodrug.
• In vitro assays using hypersialylated MDA-MB-231 breast cancer cells.

Main Results:

• Successful development of a novel lectin-directed artificial metalloenzyme (HtPA-Pd).
• The combined ArM-prodrug system exhibited biological activity against hypersialylated breast cancer cells.
• Demonstrated chemoselective activation of the doxorubicin prodrug within the tumor microenvironment.

Conclusions:

• This study presents a new ArM capable of targeting and activating cancer prodrugs.
• The developed ArM-prodrug therapy shows promise for treating hypersialylated breast cancers.
• Further research may explore broader applications of lectin-directed ArMs in cancer treatment.